SCHEMBL2840944

SCHEMBL2840944

COc1cccc2[nH]c(CCCCN)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
CYP2C19 P33261 1/20 0.45
CBFB Q13951 1/20 0.45
HSD17B10 Q99714 1/20 0.45
POLB P06746 1/20 0.43
HTR2A P28223 1/20 0.42
MAOB P27338 1/20 0.41
ADORA2A P29274 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
PARP1 P09874 1/20 0.41
HPSE Q9Y251 1/20 0.41
SLC40A1 Q9NP59 1/20 0.40
CACNA1H O95180 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23782113 0.84 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1TP53CYP3A4CYP2D6
SCHEMBL18661287 0.83 CHRM2 (0.51) SMN1; SMN2ALDH1A1TP53CYP3A4CYP2D6
SCHEMBL15767458 0.82 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1TP53CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL23782091 0.82 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1TP53CYP3A4CYP2D6
SCHEMBL2310462 0.82 HSD17B10 (0.44) SMN1; SMN2ALDH1A1TP53CYP3A4CYP2D6
SCHEMBL8314437 0.81 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1TP53CYP3A4CYP2D6
SCHEMBL2849211 0.80 PDE4A (0.38) CYP3A4CYP2D6HTR2ACACNA1HNQO2
SCHEMBL10765842 0.80 POLB (0.45) ALDH1A1CBFBPOLB
SCHEMBL2845899 0.78 POLB (0.46) POLBMAOBADORA2ASLC40A1CACNA1H
SCHEMBL15767238 0.78 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1TP53CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202885-B2 Bridged six-membered ring compounds ACTELION PHARMACEUTICALS LTD. (CH) 2012-06-19 US disclosed
US-20100130545-A1 BRIDGED SIX-MEMBERED RING COMPOUNDS IDORSIA PHARMACEUTICALS LTD (CH) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130545-A1 BRIDGED SIX-MEMBERED RING COMPOUNDS CACNA1E, CACNA1B, CACNA1A SMN1; SMN2 2919/4885ALDH1A1 1834/4885TP53 4168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.